Achaogen Awarded $24.7M Biodefense Contract by DTRA
Four-Year Contract Funds Preclinical Development of Therapies to Combat Anthrax
27-Oct-2006 -
Achaogen, Inc., a developer of antibacterial compounds, has executed a four-year contract with the Defense Threat Reduction Agency (DTRA), an agency of the United States Department of Defense, worth up to $24.7 million dollars for the development of therapies to treat anthrax and other biothreat ...
anthrax
bacteria
reductions